Yahoo · Nov 9, 2026
Orthofix Medical Inc. Q3 2026 Earnings Call Summary
Moby summary of Orthofix Medical Inc.'s Q3 2026 earnings call
NASDAQ · OFIX
Healthcare · Medical - Devices
$6.80
Down-$0.37 (-5.16%)
Updated Nov 17, 2026, 2:37 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OFIX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
OFIX closed at $6.80 after 21 trading sessions, down 29.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $7.08 | $7.15 | $6.775 | $6.80 | 604.2K |
| Nov 13, 2026 | $7.19 | $7.3164 | $7.09 | $7.17 | 553.15K |
| Nov 12, 2026 | $7.20 | $7.39 | $6.825 | $6.94 | 560.22K |
| Nov 11, 2026 | $7.02 | $7.40 | $6.94 | $7.18 | 763.52K |
| Nov 10, 2026 | $7.75 | $7.80 | $7.06 | $7.12 | 940.06K |
| Nov 9, 2026 | $7.01 | $8.03 | $6.52 | $7.90 | 2.69M |
| Nov 6, 2026 | $8.68 | $8.68 | $7.81 | $7.87 | 805.84K |
| Nov 5, 2026 | $9.95 | $10.04 | $8.645 | $8.92 | 1.36M |
| Nov 4, 2026 | $9.06 | $9.825 | $9.01 | $9.72 | 1.17M |
| Nov 3, 2026 | $8.72 | $8.85 | $8.55 | $8.76 | 402.15K |
| Nov 2, 2026 | $9.07 | $9.255 | $8.7001 | $8.75 | 565.63K |
| Oct 30, 2026 | $10.29 | $10.29 | $8.895 | $9.07 | 657.86K |
| Oct 29, 2026 | $10.22 | $10.57 | $10.125 | $10.24 | 399.26K |
| Oct 28, 2026 | $9.67 | $10.16 | $9.67 | $10.04 | 294.99K |
| Oct 27, 2026 | $9.67 | $9.94 | $9.65 | $9.71 | 301.19K |
| Oct 26, 2026 | $9.65 | $9.83 | $9.645 | $9.78 | 200.6K |
| Oct 23, 2026 | $9.92 | $9.99 | $9.67 | $9.81 | 247.6K |
| Oct 22, 2026 | $9.79 | $10.0583 | $9.79 | $9.99 | 336.77K |
| Oct 21, 2026 | $9.71 | $9.94 | $9.64 | $9.74 | 604.96K |
| Oct 20, 2026 | $9.68 | $9.95 | $9.68 | $9.85 | 335.29K |
| Oct 19, 2026 | $9.34 | $9.665 | $9.2848 | $9.59 | 296.09K |
The latest Smart Investors Daily articles mentioning OFIX.
Company
Market Activity
Research & News
OFIX research
Company profile and research snapshot.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Jul 6, 2026 | Barrington Research | Outperform | — |
| May 22, 2026 | Canaccord Genuity | Buy | — |
| May 22, 2026 | Barrington Research | Outperform | — |
| May 22, 2026 | Stifel | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 9, 2026
Moby summary of Orthofix Medical Inc.'s Q3 2026 earnings call
Yahoo · Nov 9, 2026
Orthofix Medical (NASDAQ:OFIX) lowered its 2026 outlook after third-quarter results fell short of management’s expectations, as softer U.S. spine procedure volumes and supplier delays constrained its ability to support demand. Third-quarter net sales were $207.9 million, up 2.3% year over year, wit
Yahoo · Nov 9, 2026
A U.S. Spine slump pressured results as management pushes a recovery plan.
ChartMill · Nov 9, 2026
Orthofix (OFIX) Q3 2026 adjusted EPS beat estimates, but revenue missed and FY26 guidance was cut, sending shares sharply lower.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning OFIX.